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ABSTRACT  19 
Objective: To determine the natural history of flare-ups in knee osteoarthritis and their 20 
relation to physical exposures. 21 
 22 
Design: Adults aged ≥45 years with a recent primary care consultation for knee 23 
OA/arthralgia completed a daily pen-and-paper diary for up to 3 months, including 24 
questions on average knee pain intensity, pain descriptors, other symptoms, activity 25 
interference, and selected physical exposures (prolonged kneeling, squatting, climbing 26 
stairs, ladders, and moving/lifting heavy objects). Informed by a systematic review, flare-ups 27 
were defined a priori. We calculated the rate of flare-ups in the sample, described their 28 
nature and duration, and estimated their association with physical exposures in the prior 48 29 
hours. 30 
 31 
Results: 67 participants completed at least one month of diaries,37 (55%) were female, 32 
mean age 62 years (SD 10.6) with a mean body mass index of 24.6 kg/m
2
 (SD 5.1). 30 33 
participants experienced a total of 54 flare-ups (incidence density 1.09 flare-ups/person-34 
days). The median duration of flare-ups was 8 days (range: 2-30). During a flare-up 35 
participants were more likely to report sharp, throbbing, stabbing, burning pain, swelling, 36 
limping, stiffness, being woken by pain, taking more analgesia, and stopping usual activities. 37 
Exposure to one or more physical exposure increased the risk of a flare-up in the 38 
subsequent 48 hours (odds ratio 2.19 (95%CI: 1.22, 4.05)).  39 
 40 
Conclusions: Our study with intensive longitudinal data collection suggests acute flare-ups 41 
may be experienced by a substantial number of patients. These episodes often last a week 42 
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or longer, are disruptive, prompt changes in self-management, and may be triggered by 43 
high-loading physical activities.  44 
 45 
Keywords: Knee, osteoarthritis, flare-up 46 
 47 
Running headline: Natural history of flare-ups in knee OA 48 
 49 
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INTRODUCTION  1 
 2 
Longitudinal studies following patients with symptomatic knee osteoarthritis over 3 
several years suggest that non-progressive symptom trajectories are relatively common
1
. 4 
However, within these average long-term trajectories, it is well-recognised that patients can 5 
experience substantial variability in the presence, nature, and severity of symptoms over 6 
time, including episodes of increased pain that may be experienced as acute events
2, 3
. 7 
These events, particularly when they have an unpredictable, sudden onset, can be 8 
distressing for patients and can impact on quality of life, normal activities (including 9 
productivity losses
4
) and health service use. Yet unlike other long-term conditions, there is 10 
still considerable uncertainty around the nature, definitions, and terminology of these 11 
phenomena in osteoarthritis. Classification criteria for flare-ups in knee OA have been 12 
proposed but have not been widely adopted
5
. Achieving greater clarity and agreement on 13 
these matters is an important goal for research and clinical communities
6
, toward which 14 
observational research can contribute by gaining insight into the natural history of these 15 
phenomena, possible triggers
7
, and other proximal and more distal determinants. 16 
 17 
We sought to describe the natural history of ‘flare-ups’ in knee OA in a sample of 18 
community-dwelling symptomatic adults, using an observational daily diary study. We chose 19 
the term ‘flare-up’ over terms such as ‘exacerbation’ following workshops with patients and 20 
members of the public on their preferred terminology and from more frequently used 21 
terminology in the medical literature as found in a recent systematic review
6
 22 
METHOD  23 
 24 
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Study design and sample 25 
 26 
Adults aged  45 years and over registered at one of two General Practices in the 27 
West Midlands, England and with a recorded consultation for knee osteoarthritis or knee 28 
pain/arthralgia in the previous 2 years were mailed a short questionnaire containing items 29 
used to describe the sample, judge eligibility for the daily diary study, and provide baseline 30 
values of ‘what is normal for me’ with respect to knee symptoms, activity, and analgesia 31 
(adapted from Trappenburg et al
8
). A standard three-stage mailing procedure was used with 32 
non-respondents sent a reminder postcard at two weeks and repeat questionnaire at four 33 
weeks. Respondents were eligible for inclusion in the daily diary study if they reported knee 34 
symptoms on at least one day in the previous 12 months, provided written informed 35 
consent to further contact and indicated their willingness to complete daily diaries for up to 36 
three months. Respondents were excluded if they self-reported a diagnosis of inflammatory 37 
disease, previous bilateral total knee replacement (TKR) or TKR in the index knee (the worst 38 
affected knee) or did not complete baseline knee symptom questions. 39 
 40 
Data collection 41 
 42 
All eligible, consenting questionnaire respondents were invited to complete three 43 
consecutive one-month pen-and-paper diaries. The diaries contained nine items for each 44 
day (see Supplementary Data 1) which participants were asked to fill out at the end of the 45 
day. Average pain intensity in the previous 24 hours was assessed using a 0-10 numerical 46 
rating scale (NRS)
9
. We included four single items on other symptoms shown by Marty et al
5
 47 
to be associated with OA flare-ups: stiffness lasting >20 minutes, swelling, night pain and 48 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
limping. Participants were also asked about pain quality using a short list of descriptors 49 
which included continuous pain descriptors (dull, aching, throbbing), intermittent pain 50 
descriptors (sharp, stabbing), and neuropathic-type pain descriptors (burning, numbness, 51 
pins and needles)
3, 10
.  Participants were asked if they had undertaken any of a selected list 52 
of physical activities which have previously been linked to onset of knee OA
11
. Participants 53 
were also asked about any changes in usual medication (more than normal, less than 54 
normal, the same) and whether symptoms had stopped them taking part in usual activities. 55 
 56 
The study was approved by the North of Scotland Research Ethics Committee 57 
(Reference: 13/NS/0049). 58 
 59 
Statistical analysis 60 
 61 
Scatterplots were used to visually inspect daily pain intensity scores for each participant. To 62 
estimate within-person variability we calculated a Variability Index
12
  for each participant 63 
based on the average standard deviation of their daily pain intensity scores within half-64 
monthly periods. The periods ranged from 14-16 days due to the varying length of the 65 
month over the three month study period. The standard deviation was chosen as it is the 66 
most common measure of variability which averages the absolute deviation of each day’s 67 
pain intensity from the mean pain over the 14-16 days period thus capturing any pain 68 
fluctuations.  This method has also been used in a previous study investigating pain 69 
variability of patients with fibromyalgia
12
. The 14-16 day period was chosen based on the 70 
number of available data points and to allow for reliable estimation of SD due to the 71 
distribution assumptions. The possible values were positive, with zero indicating no 72 
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variability and a higher number indicating greater variability. Informed by a systematic 73 
review of flare-up definitions in the medical literature
6
, and considering flare-up definitions 74 
used in other conditions
13
 we defined a flare-up a priori  as: an increase of at least two 75 
points from baseline (‘normal for me’) in average pain intensity in the past 24 hours (0-10 76 
NRS) which was sustained for at least two consecutive days. A flare-up was judged to be 77 
resolved when pain intensity returned to baseline level for five consecutive days.  78 
 79 
We then estimated the proportion of respondents experiencing at least one flare-up 80 
during the period of observation, the incidence density  with 95%CI of flare-ups for the 81 
sample as a whole (expressed as the number of flare-ups per 100 person-days at risk, i.e. 82 
denominator excluded days in flare-up and the five days needed for it to be judged 83 
‘resolved’) using Poisson regression taking into account recurrent events, and the duration 84 
of flare-ups (median, interquartile range (IQR)).  85 
 86 
The time course of an ‘average’ flare-up was illustrated by plotting combined group-87 
mean daily pain intensity NRS scores across all first flare-ups, anchored to a common 88 
timescale with zero representing the first day of flare-up and extending to 7 days prior and 89 
30 days after the flare-up. To describe the nature of flare-ups and their impact on 90 
individuals, descriptive statistics (means, SD or proportions) were used to summarise 91 
symptoms, change in medication and whether pain had stopped usual activities across all 92 
flare-up days and all non-flare-up days, among participants experiencing at least one flare-93 
up. We then used mixed-effect models to estimate the relative frequency (expressed as 94 
odds ratios) and severity (expressed as regression coefficients) of symptoms on flare-up 95 
versus non-flare-up days accounting for the clustered nature of the observations. 96 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
 97 
To determine whether exposure to selected physical activities was associated with 98 
flare-up onset, we conducted a case-crossover analysis with each individual acting as their 99 
own control
14
. Case windows for exposures were defined as the 48 hours prior to the first 100 
day of a flare-up. For each case we selected up to four matched ambidirectional control 101 
windows which were 48-hour periods on at-risk days which corresponded with the same 102 
days of the week as the case window to remove confounding by variation in physical 103 
exposures across days of the week (e.g. weekdays versus weekends). We calculated 104 
unadjusted exposure odds ratios (OR) based on the conditional maximum likelihood 105 
estimate with 95% mid-P exact confidence intervals using OpenEpi (www.OpenEpi.com). 106 
 107 
Analyses were performed using Stata, Version 13 (StataCorp 2013). 108 
 109 
RESULTS  110 
 111 
Of the 220 out of 330 responders to the baseline questionnaire, 106 (48%) were eligible and 112 
were invited to take part in the diary study, consented to further contact, and were mailed 113 
the first diary. Reasons for non-eligibility included; inflammatory disease (41), TKR (27), 114 
missing/blank Q (22), no recent knee pain (14), withdrew/died/moved (10). Of the 67 (63%) 115 
participants who completed at least one monthly diary, 37 (55%) were female, mean age 62 116 
years (SD 10.6) with a mean body mass index of 24.6 kg/m
2
 (SD 5.1). Of a possible 5491 117 
diary days, 4328 (79%) were fully completed, 1163 (21%) were partially completed, and 111 118 
(2%) were missed completely. Comparing responders to non-responders ages were similar 119 
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(mean age 62.2 (SD 10.6) and 61.7 (SD 11.0) respectively) and there were slightly more 120 
females amongst the non-responders (25 (64.1%) non-responders versus 37 (55.2%)). 121 
 122 
The median Variability Index across the sample was 0.68 (IQR 0.41, 1.05), and this 123 
was higher during non-flare-up days in participants classed as having experienced a flare-up 124 
than in those participants who did not experience a flare-up ((median (IQR)): 0.83 (0.51, 125 
1.13) vs 0.52 (0.27, 0.97). 126 
 127 
Over the period of observation 30 participants (45%) were classed as having 128 
experienced a total of 54 flare-ups (one flare-up (n=16), two flare-ups (n=6), three flare-ups 129 
(n=6), four flare-ups (n=2)) giving an estimated incidence density of 1.12 (95%CI 0.80, 1.57)  130 
flare-ups per 100 person-days. Illustrative examples of participants with contrasting 131 
variability in daily pain scores are provided in Supplementary Data 2.  132 
 133 
Those experiencing a flare-up were slightly more likely to be male (50% vs 40%; 134 
proportion difference (95% CI): 10% (-14%, 33%)), have a higher BMI (mean (SD) 25.5 (5) vs 135 
23.9 (6) kg/m
2
; mean difference (95% CI): 1.6( -0.9, 4.1)), and report previous injury (50% vs 136 
42%; proportion difference (95% CI): 8% (-15%, 33%)), although none of these differences 137 
were statistically significant given the relatively small numbers of participants in each group. 138 
 139 
The median duration for a flare-up was 8 days (IQR 3, 23; range 2-30). The ‘average’ 140 
time course shows the sudden onset and relatively quick reduction in pain intensity within 141 
48 hours followed by a longish plateau (Figure 1). Flare-up days compared to non-flare-up 142 
days were accompanied by a higher occurrence of knee stiffness (OR 10.9; 95% CI: 7.0, 143 
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17.1), limping (12.4;  7.4, 20.8), swelling (14.5; 8.3, 25.4), being woken by pain (7.0; 4.3, 144 
11.2), use of most pain descriptors (but particularly ‘throbbing’, ‘sharp’, ‘stabbing’ pain, and 145 
‘numbness’), interference with usual activities (26.5; 3.7, 51.5) and taking more medication 146 
than normal (23.9; 13.8, 41.4) (Table 1). The above features tended to be at their highest 147 
levels during the first two days of a flare-up (data not shown). 148 
 149 
For the case-crossover analysis using physical exposures there were 88 cases periods 150 
in total and 328 control periods. The number of control periods per case ranged from 1-4 151 
(median:2, mean: 2.43 (SD1.12)). Exposure to one or more of the selected physical 152 
exposures (prolonged kneeling, lifting/moving heavy objects, climbing several flights of 153 
stairs, prolonged squatting, climbing ladders) was associated with increased risk of acute 154 
flare-up in the subsequent 48 hours (odds ratio 2.19; 95%CI: 1.22, 4.05) (Supplementary 155 
Data 3). Exposure to each individual physical activity was positively associated with flare-up 156 
onset but estimates lacked precision due to small numbers of discordant pairs. 157 
 158 
DISCUSSION  159 
Our study supports the notion that knee OA, for some people, is characterised by 160 
intermittent acute or sudden increases in pain with an associated change in pain quality and 161 
knee symptoms.  162 
 163 
Pain intensity in our study was highly variable for some and stable for others. 164 
Although not explored in this study, Schneider et al found a link between pain variability in 165 
OA and depression
15
. Qualitative studies have highlighted the highly variable nature of pain 166 
in OA
2
 and when unpredictable can be associated with considerable distress
3
.  167 
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 168 
Predictability of pain is important for episode management and patient 169 
understanding. Prior to flare-up onset we saw a marked step up in symptoms rather than a 170 
gradual onset. This may be partly due to once daily measurement, however, we found that 171 
certain activities reported in the 48-hour period prior to a flare-up were associated with 172 
flare-up onset. Zobel et al identified that knee buckling and knee injury were triggers for 173 
acute events
7
.  Physical activity exposures have previously been associated with long term 174 
incidence of osteoarthritis
11
. The link we have found may give an insight into short term 175 
events and their intrinsic part in how OA develops and progresses. It is possible that these 176 
acute events lead to a cumulative insult on the knee joint that eventually leads to disability.   177 
 178 
Identifying potential triggers are important in the management of flare-ups in terms 179 
of activity avoidance and for earlier and preventative management strategies. Other 180 
management strategies that may lead to early termination of a flare-up include recognising 181 
the early changes in symptoms, for example knee stiffness, swelling, limping and night pain 182 
which have previously been used as part of the criteria for flare-up identification
5
. 183 
In response to flare-ups a third increased usual medication and a small number reported 184 
stopping usual activities. Our study did not capture lesser but still problematic interference 185 
with activities which may affect quality of life if sustained. We recognise that there may be 186 
potential time-varying confounders that could not be controlled in the study, for example, 187 
those causing psychosocial stress or a perceived improvement in symptoms, leading to a 188 
reduction in medication and increase in activity. 189 
 190 
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Limitations of the study include the potential for inaccurate recall of average pain 191 
scores over the 24-hour period and the extent to which participants may have 192 
retrospectively filled in diary entries. We also acknowledge the bias that may be introduced 193 
by missing data. Our case-crossover analysis was unable to explore individual physical 194 
exposures due to small numbers and the use of ambidirectional control windows assumes 195 
no strong effect of flare-ups on subsequent exposure levels.  196 
In providing an operational definition of a flare-up we recognise the need for 197 
continued empirical work. Sensitivity analyses in larger datasets could usefully explore 198 
whether absolute or relative (to baseline) increases in pain are best for defining flare-ups as 199 
well as the minimum duration of these. 200 
 201 
Conclusion  202 
 203 
Our study with intensive longitudinal data collection suggests acute flare-ups may be 204 
experienced by a substantial number of patients. These episodes often last a week or 205 
longer, are disruptive, prompt changes in self-management, and may be triggered by high-206 
loading physical activities.  207 
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FIGURE LEGENDS 279 
Figure 1. Time course of an ‘average’ flare from 7 days prior to 30 days after the onset of a 280 
flare (day 0). Points are group-mean pain intensity for all participants’ first flares combined  281 
 282 
Table 1: Table 1: Severity and occurrence of symptoms and impact experienced during flare 283 
days versus at-risk days among participants experiencing one or more flare (n=30). 284 
 285 
Supplementary data 1: Example diary page 286 
 287 
Supplementary data 2: Illustrative examples of variability in daily knee pain intensity (0-288 
10NRS) and flares for two participants 289 
 290 
Supplementary data 3: Crude ORs for physical activity exposures using discordant pairs 291 
  292 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
Table 1: Severity and occurrence of symptoms and impact experienced during flare-up 293 
days versus at-risk days among participants experiencing one or more flare-ups (n=30). 294 
 Flare-up 
days† 
(n=299) 
Non-flare-up 
days‡ 
(n=1958) 
Relative 
frequency/severity 
on flare-up days vs 
non-flare-up days* 
Average knee pain intensity (0-10NRS): 
mean (SD) 5.4 (1.9) 3.1 (2.0) 2.5 (2.3, 2.6) 
Pain descriptors    
Dull 52 (17) 673(35) 0.4 (0.2, 0.7) 
Aching 218 (73) 1122 (59) 6.9 (4.1, 11.6) 
Throbbing 95 (32) 301 (16) 18.1 (9.8, 33.3) 
Sharp 146 (49) 206 (11) 11.2 (6.8, 18.6) 
Stabbing 108 (36) 269 (14) 11.8 (7.2, 19.5) 
Burning 73 (24) 171 (  9) 6.7 (4.0, 11.1) 
Numbness 72 (24) 15 (  1) 6.7 (1.9, 23.1) 
Pins and needles 1 (<1) 1 (<1) - 
Other 9 (  3) 45 (  2) 1.3 (0.6, 3.1) 
Knee swelling 149 (50) 668 (35) 14.5 (8.3, 25.4) 
Limping 191 (64) 804 (42) 12.4 (7.4, 20.8) 
Knee stiffness lasting >20 mins 178 (60) 505 (26) 10.9 (7.0, 17.1) 
Woken at night by knee pain 103 (35) 189 (10) 7.0 (4.3, 11.2) 
Taking more medication than usual 94 (34) 181 (12) 23.9 (13.8, 41.4) 
Pain stopped usual activities 44 (15) 76 (  4) 26.5 (13.7, 51.5) 
Figures are n (%) unless otherwise stated 
† Days during a flare-up (i.e. from start of flare-up to first day when pain returned to ‘normal’ levels 
for 5 consecutive days; ‡ excludes flare-up days as well as the 5 consecutive days after last flare-up 
day    
NRS Numerical rating scale; SD Standard deviation 
*From mixed-effect model (logistic for binary and linear for continuous outcome). Results 
are expressed as odds ratios (95% CI) except average knee pain intensity which is expressed 
as a regression coefficient (i.e. mean difference) and 95% CI 
 
 295 
 296 
 297 
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Aching 218 (73) 1122 (59) 6.9 (4.1, 11.6) 
Throbbing 95 (32) 301 (16) 18.1 (9.8, 33.3) 
Sharp 146 (49) 206 (11) 11.2 (6.8, 18.6) 
Stabbing 108 (36) 269 (14) 11.8 (7.2, 19.5) 
Burning 73 (24) 171 (  9) 6.7 (4.0, 11.1) 
Numbness 72 (24) 15 (  1) 6.7 (1.9, 23.1) 
Pins and needles 1 (<1) 1 (<1) - 
Other 9 (  3) 45 (  2) 1.3 (0.6, 3.1) 
Knee swelling 149 (50) 668 (35) 14.5 (8.3, 25.4) 
Limping 191 (64) 804 (42) 12.4 (7.4, 20.8) 
Knee stiffness lasting >20 mins 178 (60) 505 (26) 10.9 (7.0, 17.1) 
Woken at night by knee pain 103 (35) 189 (10) 7.0 (4.3, 11.2) 
Taking more medication than usual 94 (34) 181 (12) 23.9 (13.8, 41.4) 
Pain stopped usual activities 44 (15) 76 (  4) 26.5 (13.7, 51.5) 
Figures are n (%) unless otherwise stated 
† Days during a flare-up (i.e. from start of flare-up to first day when pain returned to ‘normal’ levels 
for 5 consecutive days; ‡ excludes flare-up days as well as the 5 consecutive days after last flare-up 
day    
NRS Numerical rating scale; SD Standard deviation 
*From mixed-effect model (logistic for binary and linear for continuous outcome). Results 
are expressed as odds ratios (95% CI) except average knee pain intensity which is expressed 
as a regression coefficient (i.e. mean difference) and 95% CI 
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Figure 1: Time course of an ‘average’ flare-up from 7 days prior to 30 days after the onset 
of a flare (day 0). Points are group-mean pain intensity for all participants’ first flare-ups 
combined  
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